Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The SOUL study showed that adding oral semaglutide to standard care reduces the risk of major adverse cardiovascular events (MACE) by 14% in patients with type 2 diabetes and established cardiovascular or kidney disease
Data were analyzed across the full sample and with participants categorized by baseline symptom severity
Methods Mol Biol 1197:287308
Compounded 2.5mg/ml Injectable Semaglutide Suggested Dose: Inject 0.1ml once weekly subcutaneously weeks 1-4, Increase dose to 0.2ml once weekly on weeks 5-8, increase dose to 0.4ml once weekly on weeks 9-12, increase dose to 0.68ml once weekly on weeks 13-16, if a dosage increase is still needed, increase to 0.96ml once weekly for maintenance
US$ 29.46
US$ 28.92
US$ 28.84
